Cargando…

Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies

Until now, a disease-modifying therapy (DMT) that has an ability to slow or arrest Alzheimer's disease (AD) progression has not been developed, and all clinical trials involving AD patients enrolled by clinical assessment alone also have not been successful. Given the growing consensus that the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Ju-Hee, Ryoo, Na-Young, Shin, Dong Wun, Trojanowski, John Q, Shaw, Leslie M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Physiological Society and The Korean Society of Pharmacology 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296032/ https://www.ncbi.nlm.nih.gov/pubmed/25598657 http://dx.doi.org/10.4196/kjpp.2014.18.6.447

Ejemplares similares

Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges
por: Kim, Dana, et al.
Publicado: (2016)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease
por: Irwin, David J., et al.
Publicado: (2013)

The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer’s disease
por: Trombetta, Bianca A., et al.
Publicado: (2018)

Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum
por: Lee, Jongmin, et al.
Publicado: (2020)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in the Era of Disease-Modifying Treatments
por: Paraskevas, George P., et al.
Publicado: (2021)

Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers
por: Nho, Kwangsik, et al.
Publicado: (2019)

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study
por: Leung, Yuk Yee, et al.
Publicado: (2015)

Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea
por: Park, Sun Ah, et al.
Publicado: (2017)

Race modifies the relationship between cognition and Alzheimer’s disease cerebrospinal fluid biomarkers
por: Howell, Jennifer C., et al.
Publicado: (2017)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment
por: Toledo, Jon B, et al.
Publicado: (2014)

Current state of Alzheimer’s fluid biomarkers
por: Molinuevo, José Luis, et al.
Publicado: (2018)

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
por: Toledo, Jon B, et al.
Publicado: (2013)

Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
por: Huynh, Rose Ann, et al.
Publicado: (2017)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?
por: Kim, Dana, et al.
Publicado: (2014)

ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer’s disease
por: Ko, Yi-An, et al.
Publicado: (2022)

Association of serum Apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer’s pathology
por: Hu, Hao, et al.
Publicado: (2020)

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
por: Babić, Mirjana, et al.
Publicado: (2014)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
por: Bjerke, Maria, et al.
Publicado: (2018)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Their Role in Clinical Chemistry
por: Blennow, Kaj, et al.
Publicado: (2000)

Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2019)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Cerebrospinal fluid microRNAs as potential biomarkers in Alzheimer’s disease
por: Noor Eddin, Ahmed, et al.
Publicado: (2023)

Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors
por: Hajjar, Ihab, et al.
Publicado: (2022)

A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
por: Park, Sun Ah, et al.
Publicado: (2015)

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
por: Jansen, Iris E., et al.
Publicado: (2022)

Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging
por: Abner, Erin L., et al.
Publicado: (2016)

The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease
por: Mäkitalo, Signar, et al.
Publicado: (2015)

Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease
por: Sweeney, Melanie D, et al.
Publicado: (2015)

Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease
por: Alexopoulos, Panagiotis, et al.
Publicado: (2016)

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia
por: Forlenza, Orestes V., et al.
Publicado: (2015)

The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology
por: Westwood, Sarah, et al.
Publicado: (2017)

Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer’s disease
por: Ahmad, Shahzad, et al.
Publicado: (2020)

Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
por: Bader, Jakob M, et al.
Publicado: (2020)

Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimer’s Disease
por: Aksnes, Mari, et al.
Publicado: (2021)

Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
por: McGrowder, Donovan A., et al.
Publicado: (2021)

Lights and Shadows of Cerebrospinal Fluid Biomarkers in the Current Alzheimer’s Disease Framework
por: Gallucci, Maurizio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pe8os4tegc81fg4s5m4san3l5q